Skip to main content
EOFlow Co., Ltd. logo

EOFlow Co., Ltd. — Investor Relations & Filings

Ticker · 294090 ISIN · KR7294090006 KO Manufacturing
Filings indexed 460 across all filing types
Latest filing 2024-11-22 Director's Dealing
Country KR South Korea
Listing KO 294090

About EOFlow Co., Ltd.

https://www.eoflow.com

EOFlow Co., Ltd. is a medical device company that develops and provides wearable drug delivery solutions. Its flagship product is the EOPatch, a disposable, wearable insulin pump system designed for the continuous delivery of insulin to manage blood glucose levels in individuals with diabetes. The company leverages its proprietary technology and manufacturing expertise to create reliable and accessible drug delivery platforms. EOFlow also collaborates with partners to integrate its pump technology into automated insulin delivery (AID) systems, advancing diabetes care management.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the changes in share ownership by a director (Kim Jesse Jaejin) of EOFLOW Co., Ltd. This type of filing is a standard regulatory requirement for insider trading or changes in holdings by company insiders, which corresponds to the 'Director's Dealing' category.
2024-11-22 Korean
[기재정정]증권신고서(지분증권) (2024.12)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment filed by Eoflow Co., Ltd. It details specific revisions made to the original registration statement following the submission of the company's 3rd quarter report. It includes updated financial data, risk factors, and legal proceeding disclosures. As this is a formal regulatory filing document used to update information for a securities offering, it falls under the 'Regulatory Filings' category.
2024-11-18 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'EOFlow' (이오플로우) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
유상증자1차발행가액결정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Eoflow regarding the determination of the first issue price for a paid-in capital increase (rights offering). It details the calculation methodology, the specific price (4,235 KRW), and the timeline for the final price determination. This falls under the category of capital and financing updates, specifically related to share issuance and capital structure changes.
2024-10-29 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the correction of the issuance price, the purpose of the funds, the subscription method, and the timeline for the capital increase. This falls under the category of announcements regarding new share issues and capital changes.
2024-10-29 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It specifically details a correction (정정) to a previous filing regarding the determination of the issuance price (발행가액 확정) for a capital increase (유상증자). Since this is a formal regulatory filing detailing the terms of a capital raise and its subsequent price adjustment, it falls under the category of capital and financing updates.
2024-10-29 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.